Page last updated: 2024-11-05

cyclohexene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cyclohexene is a cyclic hydrocarbon with the formula C6H10. It is a colorless liquid with a pungent odor. Cyclohexene is an important intermediate in the synthesis of many industrial chemicals, including nylon and other polymers. It is also used as a solvent and as a starting material for the production of other organic compounds. Cyclohexene can be synthesized by the catalytic hydrogenation of benzene or by the dehydration of cyclohexanol. It is a relatively stable compound, but it can be oxidized to cyclohexanone or cyclohexanol. Cyclohexene is a common compound in organic chemistry and is often used as a model system for studying the properties of cyclic hydrocarbons. It is also studied for its potential use in the production of biofuels and other renewable energy sources.'

cyclohexene : A cycloalkene that is cylohexane with a single double bond. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8079
CHEMBL ID16396
CHEBI ID36404
MeSH IDM0149159

Synonyms (59)

Synonym
CHEBI:36404 ,
1-cyclohexene
benzenetetrahydride
zyklohexen
3,4,5,6-tetrahydrobenzene
1,2,3,4-tetrahydrobenzene
cyclohex-1-ene
nsc-24835
cykloheksen
110-83-8
cyclohexene
tetrahydrobenzene
nsc24835
benzene tetrahydride
benzene, tetrahydro-
wln: l6utj
1,3,4-tetrahydrobenzene
nsc 24835
einecs 203-807-8
cykloheksen [polish]
hsdb 1624
un2256
ai3-03146
hexanaphthylene
brn 0906737
inchi=1/c6h10/c1-2-4-6-5-3-1/h1-2h,3-6h
cyclohexene, inhibitor-free, reagentplus(r), 99%
CHEMBL16396
AKOS000119959
A802251
cyclohexene [un2256] [flammable liquid]
4-05-00-00218 (beilstein handbook reference)
ccris 8739
12l0p8f7gn ,
unii-12l0p8f7gn
ec 203-807-8
un 2256
FT-0624200
cyclohexene [hsdb]
cyclohexene [mi]
BP-31020
AKOS025243963
cyclo-hexene
cyclohexane n
cylcohexene
2-cyclohexen
cyclo hexene
DTXSID9038717
STL445673
J-002481
F0001-0225
mfcd00001539
cyclohexene, analytical standard
cyclohexene, contains 100 ppm bht as inhibitor, >=99.0%
Q413328
AMY17792
25012-94-6
EN300-19682
Z104474726

Research Excerpts

Effects

ExcerptReferenceRelevance
"A cyclohexene ring has similar structural properties and conformational behavior to a saturated five-membered furanose ring. "( Synthesis of 2'-cyclohexenylnucleosides and corresponding CeNA building blocks.
Di Salvo, A; Herdewijn, P; Liu, FW, 2008
)
1.07

Toxicity

ExcerptReferenceRelevance
" Amide 25 is safe in a battery of in vitro and in vivo tests and may represent a new therapeutic agent for the treatment of type 2 diabetes."( Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibi
Backes, BJ; Ballaron, SJ; Beno, DW; Fryer, RM; Judd, AS; Kempf-Grote, AJ; Li, X; Longenecker, K; Lubben, TH; Madar, DJ; Mika, AK; Mulhern, M; Pei, Z; Preusser, LC; Reinhart, GA; Sham, HL; Stashko, MA; Stewart, KD; Trevillyan, JM; von Geldern, TW; Yong, H; Zinker, BA, 2006
)
0.33

Bioavailability

ExcerptReferenceRelevance
" Optimization of the high-throughput screening lead 6 led to the discovery of 25 (ABT-341), a highly potent, selective, and orally bioavailable DPP4 inhibitor."( Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibi
Backes, BJ; Ballaron, SJ; Beno, DW; Fryer, RM; Judd, AS; Kempf-Grote, AJ; Li, X; Longenecker, K; Lubben, TH; Madar, DJ; Mika, AK; Mulhern, M; Pei, Z; Preusser, LC; Reinhart, GA; Sham, HL; Stashko, MA; Stewart, KD; Trevillyan, JM; von Geldern, TW; Yong, H; Zinker, BA, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" When dosed orally, 25 dose-dependently reduced glucose excursion in ZDF rats."( Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibi
Backes, BJ; Ballaron, SJ; Beno, DW; Fryer, RM; Judd, AS; Kempf-Grote, AJ; Li, X; Longenecker, K; Lubben, TH; Madar, DJ; Mika, AK; Mulhern, M; Pei, Z; Preusser, LC; Reinhart, GA; Sham, HL; Stashko, MA; Stewart, KD; Trevillyan, JM; von Geldern, TW; Yong, H; Zinker, BA, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cycloalkeneAn unsaturated monocyclic hydrocarbon having at least one endocyclic double bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID1149945Inhibition of chymotrypsin (unknown origin)1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Quantitative structure-activity relationship of chymotrypsin-ligand interactions.
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (200)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (4.50)18.7374
1990's9 (4.50)18.2507
2000's86 (43.00)29.6817
2010's85 (42.50)24.3611
2020's11 (5.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 78.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index78.21 (24.57)
Research Supply Index5.33 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index135.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (78.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.49%)5.53%
Reviews5 (2.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other198 (97.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]